Hydroxycarbamide (Siklos®)

Assessment Status Assessment process complete
HTA ID -
Drug Hydroxycarbamide
Brand Siklos®
Indication For use in the prevention of painful, recurrent vaso-occlusive crises, including acute chest syndrome, in adults, adolescents and children over 2 years of age suffering from symptomatic sickle-cell disease.
Assessment Process
Rapid review commissioned 22/08/2011
Rapid review completed 06/09/2011
Rapid review outcome Full Pharmacoeconomic Evaluation not Recommended.